NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Virogin Biotech

Virogin Biotech

Private
RichmondHealthcare & Life Scienceshttps://virogin.com/

Last Round

Series D

Sep 24, 2021

Total Funding Raised

$279M

Company Overview

Virogin Biotech is a clinical-stage immuno-oncology company developing oncolytic virotherapy and mRNA-based therapeutics to elicit an anti-tumor immune response against solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncolytic virusimmuno-oncologycancer immunotherapyviral engineeringsolid tumor treatmentbiopharmaceuticalclinical-stage biotechdrug discoveryclinical trialstumor microenvironmentoncolytic virotherapycancer drug developmentbiotech licensingHSV-1immune-modulating payloads

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Virogin Biotech Comparables

Compare Virogin Biotech with similar companies based on industry and business-model similarity.

Virogin Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Binhui Biopharmaceutical Co., Ltd.
88%
ImmVira
87%
TILT Biotherapeutics
87%

Virogin Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 24, 2021
Series CSep 21, 2020
Series BDec 4, 2018

Key People

Founding team and executive leadership

William Jia

Co-founder And Chief Scientific Officer

Founding Team

Chris Huang

Chief Executive Officer And Co-Founder

Founding Team

Yanlei Chen

CEO Board Secretary

Executive Team

Virogin Biotech Investors

Notable investors and investment history

Virogin Biotech investors
InvestorRounds
Korea Investment PartnersSeries C
健壹资本Series B
SDIC Venture CapitalSeries C
Panlin CapitalSeries C, Series D
CDH InvestmentsSeries C

Virogin Biotech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Virogin Biotech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Virogin Biotech's valuation, stock price, and market status.

Firmographic Details

HeadquartersRichmond
Employee Range29
Year Founded2015
Last FundingSep 24, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.